Anteris Technologies
Anteris Technologies is an Australian medical technology company known for developing the DurAVR™ THV, a biomimetic aortic valve, and for raising significant funding to support its clinical trials and expansion.
Company Overview
Anteris Technologies develops innovative solutions in the field of cardiovascular health. It is known for the DurAVR™ THV, a biomimetic valve designed to replicate the function of a healthy human aortic valve. The company is headquartered in Toowong, Queensland, Australia, with additional offices in Eagan, Minnesota, USA, and Geneva, Switzerland. Anteris Technologies was named MedTech Outlook's Company of the Year for 2023.
Flagship Product: DurAVR™ THV
The DurAVR™ THV is Anteris Technologies' premier product. This first-in-class biomimetic valve is engineered to mimic a healthy pre-disease human aortic valve. Clinical trials, including First-in-Human studies, have demonstrated excellent haemodynamic performance at 12 months. The DurAVR™ THV leverages ADAPT® anti-calcification tissue technology, used clinically for over a decade in more than 50,000 patients.
Clinical Trials and Research
Anteris Technologies conducts thorough clinical trials to evaluate the DurAVR™ THV. First-in-Human studies have shown significant positive outcomes, including remarkable haemodynamic performance at the 12-month mark. These trials are critical in validating the safety and efficiency of the DurAVR™ THV, paving the way for broader medical adoption.
Innovative Technologies: ADAPT® and ComASUR™
Anteris Technologies utilizes ground-breaking technologies in its products. The company’s ADAPT® anti-calcification tissue technology has a successful clinical use record, extending over 10 years and benefiting over 50,000 patients worldwide. Additionally, the ComASUR™ Delivery System offers a balloon expandable mechanism that ensures controlled deployment and accurate placement of the DurAVR™ THV.
Funding and Investment
In an effort to support FDA Pivotal trials and other operational needs, Anteris Technologies has raised $40 million through the issuance of new shares. Additionally, the establishment of a sponsored Level 1 American Depository Receipt (ADR) program extends its reach to U.S. investors, enhancing access to its shares.